1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register
(
- Contribution to journal › Article
-
Mark
Exploration of real-world outcomes and treatment patterns in patients treated with anti-vascular endothelial growth factors for neovascular age-related macular degeneration in Sweden
(
- Contribution to journal › Article
- 2021
-
Mark
Treatment of age-related macular degeneration after cataract surgery : a study from the Swedish National Cataract and Macula Registers
(
- Contribution to journal › Article
- 2020
-
Mark
Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)
(
- Contribution to journal › Article
- 2019
-
Mark
Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration : data from the INSIGHT study using the Swedish Macula Register
(
- Contribution to journal › Article
- 2018
-
Mark
Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration
(
- Contribution to journal › Article
- 2017
-
Mark
RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
(
- Contribution to journal › Article
-
Mark
Treatment for neovascular age-related macular degeneration in Sweden : outcomes at seven years in the Swedish Macula Register
(
- Contribution to journal › Article
- 2016
-
Mark
Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden
(
- Contribution to journal › Article